In October 2019, the National Institute for Health and Care Excellence (NICE) published one new interventional procedure guidance (for midcarpal hemiarthroplasty for wrist arthritis) and two new MedTech innovation briefings (for superDimension Navigation System to help diagnostic sampling of peripheral lung lesions and MR-proADM test for use with clinical deterioration scores in cases of suspected infection).
Interventional Procedure Guidance is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from ‘for research only’ to ‘for use with standard arrangements for clinical governance, consent, and audit.' Recommendations are not binding, although they are followed by providers and commissioners.
In October 2019, NICE published one new Interventional Procedure Guidance for Midcarpal hemiarthroplasty for wrist arthritis, which covers evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. Evidence on the safety and efficacy of midcarpal hemiarthroplasty for wrist arthritis is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.
MedTech Innovation Briefing is the NICE's advice program for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations.
Two new Medtech Innovation Briefings for superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (used to guide endoscopic tools or catheters during biopsy of mediastinal and peripheral lung lesions) and MR-proADM test for use with clinical deterioration scores in cases of suspected infection (an automated immunofluorescent assay that measures the blood-based biomarker, mid-regional pro adrenomedullin (MR-proADM) in human ethylenediaminetetraacetic acid (EDTA) plasma) have been published in October.
See the full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.